Business Context and Reporting Period
This Form 6-K is filed by Apollomics Inc. for the month of July 2025, dated July 25, 2025. The filing addresses a material dispute regarding a commercialization agreement for the Company's proprietary c-Met inhibitor, vebreltinib, with LaunXP International Co., Ltd. ("LaunXP").
Key Financial Metrics and Liquidity
- Cash and Cash Equivalents: As of June 30, 2025, the Company held $2.1 million, with $1.0 million held outside of China.
- Contractual Receivables: Under the Agreement with LaunXP, Apollomics is entitled to $10 million in upfront payments. As of the filing date, $1.3 million has been received, leaving $8.7 million outstanding.
- Liquidity Outlook: Future liquidity through December 31, 2025, is explicitly contingent upon the receipt of the remaining $10 million upfront payment from LaunXP.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or margin figures for the reporting period.
Material Changes and Dispute Details
The primary material change is the escalation of a payment dispute with LaunXP regarding the vebreltinib development and commercialization agreement in Asia (excluding mainland China, Hong Kong, and Macau).
- Breach Notification: Apollomics notified LaunXP of a failure to cure a breach within the permitted period and intends to pursue remedies.
- Counter-Claim: LaunXP has responded by asserting it is not in breach and claims Apollomics has not satisfied its own obligations under the Agreement.
- Current Status: The parties are actively engaged in discussions to resolve the matter.
Outlook, Risks, and Management Commentary
Management has issued a severe warning regarding the Company's financial stability. The filing states that LaunXP's continued failure to pay the remaining $8.7 million will have a material adverse effect on liquidity, financial condition, and results of operations.
- Going Concern Risk: The Company explicitly states that non-payment may render it insolvent and unable to sustain operations or continue as a going concern.
- Uncertainty of Recovery: Apollomics cannot assure investors that it will receive any of the $8.7 million owed, nor can it predict when such payments might be received if the dispute is resolved.
Investor Verification Checklist
- Verify the current status of the legal dispute and any potential litigation filings between Apollomics and LaunXP.
- Confirm the Company's actual cash burn rate and runway given the $2.1 million cash balance as of June 30, 2025.
- Assess the likelihood of recovering the $8.7 million outstanding upfront payment based on ongoing negotiations.
- Review the specific contractual obligations cited by LaunXP regarding Apollomics' alleged failure to perform.
- Monitor for any subsequent filings regarding insolvency proceedings or emergency financing efforts.